Loading...
A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors
LESSONS LEARNED: The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified. The mean...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018307/ https://ncbi.nlm.nih.gov/pubmed/33105036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13577 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|